Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +75

Assessing Bristol Myers Squibb (BMY) Valuation After Camzyos Data And T Cell Engager Collaboration News

AI-generated analysis

📈 Bristol-Myers Squibb (BMY) shares closed at US$59.47, reflecting positive momentum following recent data releases and partnerships.

💖 The company released positive Phase 3 data for its drug Camzyos in adolescents with obstructive hypertrophic cardiomyopathy.

🤝 BMY announced a new multi-year collaboration to develop T-cell engager therapeutics with Oxford BioTherapeutics.

📊 Year-to-date share price return stands at 11.24%, contributing to an annualized total shareholder return of 23.74%.

💰 At the current share price, BMY trades at a discount to its average analyst target price of US$63.04.

📉 Full-year 2024 revenues reached $48.3 billion, representing a 7% increase compared to 2023.

❌ GAAP loss per share widened to $(4.41) in 2024 from earnings of $3.86 in 2023 due to investment and restructuring costs.

📈 Non-GAAP EPS decreased significantly to $1.15, down from $7.51 in the previous year.

🌱 Growth portfolio revenues jumped 17% year-over-year to $22.6 billion, indicating strong performance of newer products.

💡 Simply Wall St calculates a fair value of US$65.00 for BMY, suggesting the stock is currently undervalued by roughly 9%.

⚠️ Investors face risks if growth portfolio momentum slows or if cost savings fail to stabilize reported profitability.

🛡️ Simply Wall St highlights that the company holds a "fair value" narrative despite current GAAP losses driven by strategic investments.

🔄 The investment thesis relies on newer products driving future margins and valuation rather than legacy oncology earnings alone.

Bullish Signals
  • Bristol-Myers Squibb announced positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy, strengthening its pipeline.
  • A new multi-year T-cell engager collaboration with Oxford BioTherapeutics adds significant oncology potential to the company's portfolio.
  • Growth Portfolio Revenues reached $22.6 billion, representing a robust 17% increase from 2023, highlighting strong performance of newer products.
  • Total shareholder return over the past year was 23.74%, demonstrating building momentum around recent Camzyos data and oncology collaborations.
  • The stock currently trades at a modest discount to analyst targets with a fair value assessment of $65.00 versus the current price of $59.47, suggesting potential upside.
  • Full-Year 2024 Total Revenues were $48.3 billion, marking a 7% increase from 2023.
  • Non-GAAP EPS for 2024 was $1.15, indicating profitability metrics despite GAAP loss.
  • Analyst consensus suggests the stock is undervalued with a calculated fair value of $65.00.
  • The company's focus on a growing set of newer products supports long-term revenue growth.
  • Recent positive catalysts including Camzyos data and new collaborations have strengthened investor sentiment.
Risk Factors
  • GAAP loss per share widened significantly to $(4.41) from earnings of $3.86 in 2023, indicating deteriorating core profitability despite overall revenue growth.
  • Non-GAAP EPS dropped substantially from $7.51 in 2023 to just $1.15, suggesting a potential mismatch between current valuation assumptions and recent earnings performance.
  • The company is trading at a share price of US$59.47 against a fair value target of US$65.00, but the gap relies on future growth momentum that could easily reverse if newer product sales slow down.
  • Analyst consensus targets the stock at US$63.04, meaning current investor sentiment may already be pricing in some positive developments from recent clinical trial data and collaborations.
  • The valuation narrative depends heavily on cost savings successfully translating into stable reported profitability, creating a key risk if management fails to deliver on efficiency gains.
Full Analysis
Bristol-Myers Squibb (NYSE: BMY) has garnered renewed attention following the release of positive Phase 3 data for its drug Camzyos in adolescents with obstructive hypertrophic cardiomyopathy and the announcement of a multi-year collaboration focused on T-cell engager therapeutics with Oxford BioTherapeutics. The company is currently trading at a share price of US$59.47, which corresponds to a nine-day return of 6.46% and an 11.24% year-to-date gain, while the one-year total shareholder return stands at 23.74%. Analysts and the platform analyzing the stock suggest that these positive developments in late-stage pipeline news are driving momentum for the healthcare giant. Financially, Bristol-Myers Squibb reported full-year 2024 revenues of $48.3 billion, representing a 7% increase from 2023 figures. Despite a GAAP loss per share of $(4.41) compared to $3.86 in 2023, the company demonstrated resilience with non-GAAP earnings per share of $1.15 and significant growth in its newer product portfolio, which generated $22.6 billion in revenue, a 17% increase from the previous year. The analysis indicates that the current market price of US$59.47 trades at a discount to both the US$63.04 average analyst target and a calculated fair value narrative of US$65.00, leading analysts to classify the stock as undervalued with a value score of 5. The positive valuation outlook relies heavily on the sustained momentum of its growing portfolio of newer products alongside optimistic margin assumptions. However, there are significant risks that could challenge this bullish narrative, specifically if growth portfolio momentum slows down or if projected cost savings and earnings guidance fail to translate into more stable reported profitability. The article notes that investor opinions remain split between concerns over these potential headwinds and optimism regarding the upcoming rewards from recent data releases and partnerships, resulting in a fair value assessment that suggests the gap between the current price and the US$65.00 fair value is hard to ignore.